Every 8-K that Voyager Acquisition Corp Warrants (VACHW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VACHW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VACHW filings page.
Voyager Acquisition Corp. and Veraxa Biotech agreed to a financing package to support their planned business combination and Veraxa’s growth. Veraxa’s holding company, PubCo, will privately issue $27.5 million of senior secured notes due in 15 months, plus warrants to buy 2,391,305 ordinary shares at $11.50 per share. The notes feature monthly redemptions of $2.75 million, a 15% default interest rate and a 20% cash sweep from certain future equity financings, and are secured by substantially all group assets. PubCo also entered into a share purchase agreement with Lincoln Park Capital, giving it the right, but not the obligation, to sell up to $50 million of stock over 24 months at discounts to market, subject to a 4.99% beneficial ownership cap, adjustable to 9.99%. PubCo will issue $750,000 of shares to Lincoln Park as consideration and plans to use proceeds primarily for working capital, corporate purposes and limited underwriter compensation.
Voyager Acquisition Corp. shareholders approved its business combination with VERAXA Biotech AG and related merger and charter proposals at a March 12, 2026 meeting. Holders of 25,217,315 Class A shares, representing approximately 99.67% of the Class A shares outstanding, exercised redemption rights. Assuming these elections are not withdrawn, about $885,556 will remain in the trust account and 82,685 Class A shares will convert into shares of the combined company, Veraxa Biotech Holding AG, which is expected to trade on Nasdaq under the symbol VRXA once closing conditions and listing approvals are satisfied.
Voyager Acquisition Corp. filed an update stating that VERAXA Biotech AG shareholders approved the merger structure with Veraxa Biotech Holding AG and the issuance of new shares to Voyager in connection with their proposed business combination.
At an Extraordinary General Meeting on February 27, 2026, VERAXA shareholders approved an absorption merger under which Veraxa Biotech Holding AG will acquire VERAXA and then be renamed Veraxa Biotech AG, with VERAXA continuing under its existing management. The meeting also approved an ordinary capital increase of up to CHF 223,400.00, with the corresponding number of shares to be offered to Voyager shareholders as part of the transaction. Completion of the business combination and listing of the combined company on Nasdaq under the symbol “VRXA” remain subject to Voyager shareholder approval and other closing conditions.
Voyager Acquisition Corp. updated the terms of its planned merger with Veraxa Biotech AG. The parties signed a Second Amendment to their Business Combination Agreement, increasing the aggregate merger consideration to $1,350,000,000 from $1,300,000,000.
Veraxa agreed to waive a condition in the existing agreement so Voyager can ask its shareholders to amend its charter to remove a net tangible asset requirement of $5,000,001. This change is aimed at giving the company flexibility to complete the deal even with higher shareholder redemptions.
Separately, Voyager’s sponsor agreed in a First Amendment to the Sponsor Support Agreement that, at closing, it will forfeit for cancellation 200,000 Class B ordinary shares and 400,000 SPAC warrants for no consideration. An equivalent number of PubCo ordinary shares and PubCo warrants will instead be issued to Veraxa shareholders, modestly shifting economics toward the target’s owners.
Voyager Acquisition Corp. filed a report furnishing an investor presentation for its proposed business combination with Veraxa Biotech AG. The presentation, dated September 5, 2025, is provided as Exhibit 99.1 and is intended for distribution to investors and use in in-person presentations describing the planned transaction among Voyager, Veraxa Biotech AG, Veraxa Biotech Holding AG (PubCo), and Veraxa Cayman Merger Sub.
The report emphasizes that the information in the presentation is being furnished under Regulation FD and is not deemed filed for liability purposes under U.S. securities laws. It includes extensive cautionary language on forward-looking statements, outlining numerous risks that could cause actual results to differ from projections, and explains that a registration statement on Form F-4 and proxy materials will be filed for shareholder consideration of the business combination.